- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05167669
Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU (BM-RT-HIFU)
Pain Relief in Patients With Symptomatic Bone Metastases: a Feasibility Pilot Study on Palliative Radiotherapy With Adjuvant Hyperthermia by Magnetic Resonance-guided Focused Ultrasound
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Metastatic disease to the bone is a common cause of pain and other significant symptoms with a detrimental impact into quality of life. Up to 85% of the patients dying from breast, prostate, or lung cancer present bone metastases. External beam radiation therapy (EBRT) is one of the standard palliative treatment modalities effective in palliating painful bone metastases. Using patient-based evaluation method, pain improvement is observed in 60% to 80% of the patients, with 15% to 40% complete pain relief. Combination of hyperthermia (HT) with radiation is strongly compelling as it is based on principles of classic radiobiology, molecular biology, and tumor physiology. Elevating temperature to a supra-physiological level (between 41° and 43°) shows a complementary action when combined with RT with regard to cell killing. Magnetic resonance (MR) imaging is commonly used in clinical routine for radiological diagnostic and staging. Moreover, MR is providing accurate, tissue-independent thermometry for intra-procedural guidance of thermal therapy. In this project we aim to combine in an adjuvant setting mild hyperthermia to EBRT for sustained relief of pain in patients with symptomatic bone metastases. Ex vivo studies for the adaptation of existing MR-guided focused ultrasound (MRgFUS) device were already conducted at University Hospitals of Geneva to the current application demonstrating the high accuracy of the technique for mild hyperthermia treatments. A clinical prospective, interventional, single-center pilot feasibility study will be conducted to assess the clinical application of this technique.
Primary objective
- Accurate control of spatio-temporal pixel-wise MR thermometry (several hundred pixels): spatial homogeneity of temperature elevation within the tumour and inter-patient reproducibility (expected standard deviation of 0.5°C).
- Safety and patient tolerance: no adverse effects in surrounding bone and soft tissues, compliance with one-day dual treatment during the first month.
Secondary objectives
- Complete pain response at 28 days after EBRT + HT based on the International Bone Metastases Consensus Endpoint definition.
- Pain assessment for the worst pain related to the treated lesion using the Brief Pain Inventory score at baseline, at day 1, day 7, and 28 days after treatment after EBRT + hyperthermia.
- Health-related quality of life evaluated using self-administered EORTC QLQ-C15-PAL and EORTC QLQ-BM22 (bone metastases module) questionnaires at baseline, day 7, and day 28 after EBRT + hyperthermia.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: sana boudabbous, MD PD
- Phone Number: 0041795532444
- Email: sana.boudabbous@hcuge.ch
Study Locations
-
-
-
Geneva, Switzerland, 1205
- Recruiting
- University Hospitals of Geneva
-
Contact:
- Sana Boudabbous, Dr
- Email: sana.boudabbous@hcuge.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• Histologically proven cancer;
- cancer-related pain corresponding to a site (or sites) of radiologically confirmed bone metastases with a severity score of at least 2 out of 10 according to the Brief Pain Inventory (NRS scale);
- age ≥ 18 years;
- indication for a palliative course of EBRT;
- osteolytic or mixed (osteoblastic/osteolytic) bone metastases ≤ 5 cm in the largest diameter; target tumours accessibility for device (ribs, extremities, pelvis, shoulders or posterior aspects of spinal vertebra) and at least 1 cm from skin and major nerve bundles;
Exclusion Criteria:
- Inability to provide a written informed consent;
- Karnofsky performance status (KPS) < 60; presence of clinical or radiological evidence of spinal cord compression, a pathological fracture, or an impending fracture needing surgical fixation;
- previous EBRT to study site (or sites);
- participation in another clinical trial and any concurrent treatment with any investigational drug within 4 weeks prior to trial entry;
- inability to comply with study and follow up procedures;
- patients having metal implants, pacemakers or clustered markers non-MR compatible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Prospective, interventional, single-center, feasibility pilot study.
10 patients with radiologically confirmed bone metastases and eligible for a course of palliative EBRT.
Eligible patients will be mainly discussed and recruited in a dedicated tumor-board for bone metastases performed in a weekly basis at HUG.
|
HIFU application under MRI guiding to deliver hypothermia to eligible bone metastases before clinical indicated radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accurate elevation of temperature measured by MRI thermometry (degree celsius)
Time Frame: day 1
|
Accurate control of spatio-temporal pixel-wise MR thermometry (several hundred pixels): spatial homogeneity of temperature elevation within the tumour and inter-patient reproducibility (expected standard deviation of 0.5°C).
|
day 1
|
Safety and patient tolerance according to The adverse events (CTCAE v5.0) (Art. 2 Abs 58 MDR)
Time Frame: day 1
|
Safety and patient tolerance: no adverse effects in surrounding bone and soft tissues, compliance with one-day dual treatment during the first month. Dermatitis of grade 3 or more - Pain of skin grade 3
|
day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete pain response according to International Bone Metastases Consensus Endpoint score (BPI score)
Time Frame: at 28 days after EBRT + HT
|
Complete pain response based on the International Bone Metastases Consensus Endpoint definition.
|
at 28 days after EBRT + HT
|
Pain assessment using Brief Pain Inventory score (BPI score)
Time Frame: at day 1, day 7, and 28 days after treatment after EBRT + hyperthermia.
|
Pain assessment for the worst pain related to the treated lesion using the Brief Pain Inventory score
|
at day 1, day 7, and 28 days after treatment after EBRT + hyperthermia.
|
quality of life using EORTC QLQ-C15-PAL (bone metastases module) questionnaires.
Time Frame: day 1, day 7, and 28 days after EBRT + hyperthermia.
|
Health-related quality of life evaluated using self-administered EORTC QLQ-C15-PAL (bone metastases module) questionnaires
|
day 1, day 7, and 28 days after EBRT + hyperthermia.
|
quality of life using EORTC QLQ-BM22 (bone metastases module) questionnaires.
Time Frame: day 7, and day 28 after EBRT + hyperthermia.
|
Health-related quality of life evaluated using self-administered EORTC QLQ-BM22 (bone metastases module) questionnaires
|
day 7, and day 28 after EBRT + hyperthermia.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-02998
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MRI
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
PfizerCompletedMRI SedationUnited States, Japan
-
University of UtahWithdrawnMRI ScansUnited States
-
Rennes University HospitalRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of LiegeUnknown
-
SpinTech, Inc.University of Iowa; University of Texas Southwestern Medical Center; Loma Linda... and other collaboratorsCompleted
Clinical Trials on HIFU-MRI guided
-
Philips HealthcarePhilips Medical SystemsCompletedUterine FibroidsKorea, Republic of, Netherlands, France, Germany
-
Sunnybrook Health Sciences CentreSunnybrook Research Institute; Arrayus Technologies Inc.Active, not recruiting
-
Turku University HospitalRecruitingAdenomyosis | Uterine FibroidsFinland
-
Philips HealthcareCompleted
-
Turku University HospitalUniversity of TurkuActive, not recruitingBenign Prostatic Hyperplasia | Locally Advanced Prostate Cancer | Locally Recurrent Prostate Cancer | Localised Prostate CancerFinland
-
Philips HealthcareCompletedUterine Fibroids | Uterine LeiomyomataUnited States
-
Philips HealthcareCompletedUterine LeiomyomasCanada
-
Philips HealthcarePhilips Medical SystemsCompleted
-
Institute of Cancer Research, United KingdomCompletedCervical Cancer | Ovarian Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Uterine CancerUnited Kingdom
-
Institute of Cancer Research, United KingdomCancer Research UK; Philips Medical SystemsWithdrawnCancer | Bone MetastasesUnited Kingdom